- Home
- SGA vs FBIO Comparison
SGA vs FBIO Comparison
Compare SGA & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- FBIO
- Stock Information
- Founded
- SGA 1986
- FBIO 2006
- Country
- SGA United States
- FBIO United States
- Employees
- SGA N/A
- FBIO N/A
- Industry
- SGA Broadcasting
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- FBIO Health Care
- Exchange
- SGA Nasdaq
- FBIO Nasdaq
- Market Cap
- SGA 78.8M
- FBIO 88.7M
- IPO Year
- SGA 1992
- FBIO N/A
- Fundamental
- Price
- SGA $12.18
- FBIO $2.53
- Analyst Decision
- SGA
- FBIO Strong Buy
- Analyst Count
- SGA 0
- FBIO 2
- Target Price
- SGA N/A
- FBIO $16.50
- AVG Volume (30 Days)
- SGA 6.2K
- FBIO 443.8K
- Earning Date
- SGA 11-06-2025
- FBIO 11-12-2025
- Dividend Yield
- SGA 8.26%
- FBIO N/A
- EPS Growth
- SGA N/A
- FBIO N/A
- EPS
- SGA 0.03
- FBIO N/A
- Revenue
- SGA $109,822,000.00
- FBIO $59,301,000.00
- Revenue This Year
- SGA N/A
- FBIO $31.85
- Revenue Next Year
- SGA $5.37
- FBIO $44.43
- P/E Ratio
- SGA $415.37
- FBIO N/A
- Revenue Growth
- SGA N/A
- FBIO N/A
- 52 Week Low
- SGA $10.75
- FBIO $1.33
- 52 Week High
- SGA $14.27
- FBIO $4.20
- Technical
- Relative Strength Index (RSI)
- SGA 45.89
- FBIO 40.17
- Support Level
- SGA $11.89
- FBIO $2.39
- Resistance Level
- SGA $12.45
- FBIO $2.65
- Average True Range (ATR)
- SGA 0.30
- FBIO 0.13
- MACD
- SGA -0.02
- FBIO -0.00
- Stochastic Oscillator
- SGA 26.36
- FBIO 26.80
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.